In this episode of Investor Connect, we welcome Ken from Synaptically, who introduces a groundbreaking personalized therapy for Alzheimer's disease. He discusses their innovative use of Transcranial Magnetic Stimulation (TMS) paired with Electroencephalograms (EEG) to achieve unprecedented results in slowing down disease progression.

With two successful phase two clinical trials and strong validation from scientific experts, the therapy shows significant improvements in cognition, function, and behavior in patients. Ken explains how their technology targets neuroplasticity, creating new brain connections and preserving brain microstructure and gray matter volume, with minimal side effects.

The discussion also touches on Synaptically's strong financials, market strategy, and future prospects, including potential FDA approval and investment opportunities for interested parties.

Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding.

Let’s go startup something today.

_______________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https://tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.